Skip to main content

Biomerica Launches AI-Backed inFoods® IBS Trigger Food Navigator to Support Personalized IBS Therapy and Improve Patient Outcomes

Written by Customer Service on . Posted in Public Companies.

  • New AI-enabled digital tool empowers patients to confidently manage IBS symptoms and avoid the trigger foods identified by inFoods® IBS testing
  • IBS affects an estimated 40 million adults in the U.S. and hundreds of millions worldwide

IRVINE, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) — Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced diagnostic and therapeutic solutions, today announced the launch of its inFoods® IBS Trigger Food Navigator, a comprehensive AI-backed digital companion tool designed to better enable patient dietary compliance and improve treatment success for individuals with Irritable Bowel Syndrome (IBS).

The inFoods® IBS test identifies, on average, two to four specific foods that trigger a patient’s IBS symptoms, leading to a simple, highly targeted and actionable dietary plan. The new AI-backed Trigger Food Navigator builds on this therapeutic technology by making it even easier for patients to follow their personalized dietary plan through smart meal suggestions, ingredient substitutions, and simplified meal planning tools.

Simplifying Dietary Adherence for Lasting Relief

Because the inFoods® IBS test pinpoints only a few trigger foods, most patients can continue enjoying the majority of the foods currently in their diets, with small adjustments. This is vastly easier for patients than traditional restrictive diets that often eliminate entire food categories.

“Unlike broad elimination diets, inFoods IBS has the ability to identify select and specific IBS trigger foods, which makes compliance more achievable,” said Zack Irani, CEO of Biomerica. “The new AI-backed Trigger Food Navigator takes this one step further by guiding patients through everyday food choices and offering easy substitutions. This empowers patients to stick with their personalized plan, leading to greater adherence, better symptom relief, and a significant improvement in quality of life — all while strengthening the relationship between patients and their healthcare providers.”

Clinical Results

Findings from the pivotal inFoods® IBS clinical study and a follow-up patient success study confirmed significant symptom relief, including improvements in bloating, abdominal pain, and overall quality of life. In the largest study of its kind, recently published in the June 2025 issue of Gastroenterology, inFoods IBS demonstrated the following statistically significant outcomes:

  • 59.6% of patients in the treatment group (who eliminated identified trigger foods) achieved the FDA’s endpoint for abdominal pain reduction, compared to 42.2% in the control group.
  • Among IBS-C patients, 67.1% of patients in the treatment group vs. 35.8% in the control group.
  • Among IBS-M patients, 66.0% of patients in the treatment group vs. 29.5% in the control group.

Key Features of the AI-Backed inFoods® IBS Trigger Food Navigator

Developed in collaboration with leading dietitians from the University of Michigan, ensuring accurate, expert-backed dietary guidance, the inFoods IBS trigger Food Navigator offers:

  • Smart Food Identification – Patients can instantly check whether a meal contains their unique trigger foods.
  • AI-Driven Personalized Meal Suggestions – Curated meal recommendations tailored to individual dietary restrictions.
  • Alternative Food Database – Understanding of hidden or alternative ingredient names on food labels to avoid accidental consumption.
  • Meal Planning & Export – Saving and exporting of favorite meals plans as shareable PDFs.

Benefits for Patients and Providers

  • Improved Patient Compliance: Makes dietary changes simple, achievable and sustainable.
  • Better Treatment Outcomes: Leads to greater and lasting symptom relief.
  • Reduced Anxiety: Helps patients confidently navigate food choices and substitutions.
  • Extended Care Between Visits: Enhances patient-provider relationships by supporting patients outside the clinic.
  • Improved Quality of Life: Empowers patients to live with fewer symptoms and less disruption, vastly improving quality of life.

Access and Integration

The Navigator is included at no additional cost for patients who have already purchased the inFoods® IBS test. Access is activated using a purchase confirmation code. For new patients, the inFoods® IBS test and Navigator can be easily ordered through participating healthcare providers or online.

A demonstration video is available to showcase how the Navigator simplifies meal planning and enhances treatment success.

About Biomerica (NASDAQ: BMRA)
Biomerica, Inc. (www.biomerica.com or www.inFoodsIBS.com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians’ offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company’s products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focuses on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development. For more information, visit www.infoodsibs.com and www.biomerica.com.

About inFoods®
inFoods® IBS is a diagnostic-guided therapy that identifies patient-specific food triggers responsible for symptoms such as abdominal pain, bloating, diarrhea, and constipation. Using a simple finger-stick blood sample, the test enables physicians to recommend targeted dietary changes tailored to the patient’s immune response—offering a non-pharmaceutical, precision-based approach to symptom relief.

A multicenter, double-blind clinical study on the inFoods® IBS test was published in the June issue of Gastroenterology, the top peer-reviewed GI journal. As the largest study of its kind, it demonstrated statistically significant outcomes:

  • 59.6% of patients in the treatment group (who eliminated identified trigger foods) achieved the FDA’s endpoint for abdominal pain reduction, compared to 42.2% in the control group.
  • Among IBS-C patients, 67.1% of patients in the treatment group vs. 35.8% in the control group.
  • Among IBS-M patients, 66.0% of patients in the treatment group vs. 29.5% in the control group.

These results highlight inFoods® IBS as the only targeted therapy to demonstrate efficacy specifically in IBS-M patients, a subgroup historically underserved by existing treatments. The study was conducted at leading U.S. institutions including Cleveland Clinic, Mayo Clinic, University of Michigan, and Beth Israel Deaconess Medical Center.

For more information about inFoods® IBS, visit www.inFoodsibs.com.

inFoods IBS is Laboratory Developed Test (LDT) used within a single laboratory that is certified under the Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity testing.

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking, such as statements relating to the Company’s current and future sales, revenues, overhead, expenses, cost of goods, operations and earnings, efficacy of the Company’s products and tests including, and quality, accuracy and efficacy of the information provided on the inFoods IBS Trigger Food Navigator system. future use of the Company’s products by physicians to treat their patients, potential revenues from the sale of current or future products. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results, in the future, including, without limitation: earnings and other financial results; results of studies testing the efficacy of the Company’s inFoods tests and other products; regulatory approvals necessary prior to commercialization of the Company’s products; availability of the Company’s test kits and other products; capacity, shipping logistics, resource and other constraints on our suppliers; dependence on our third party manufacturers; dependence on international shipping carriers; governmental import/export regulations; demand for our various tests and other products; competition from other similar products and from competitors that have significantly more financial and other resources available to them; governmental virus control regulations that make it difficult or impossible for the company to maintain current operations; regulatory compliance and oversight, and the Company’s ability to obtain patent protection on any aspects of its diagnostic or therapeutic technologies. Accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. Additionally, potential risks and uncertainties include, among others, fluctuations in the Company’s operating results due to its business model and expansion plans, downturns in international and or national economies, the Company’s ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company’s dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.

Corporate Contact:

Zack Irani | CEO
p. 949.645.2111
www.biomerica.com

Source: Biomerica

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.